TCTMD reports that two novel incretin-based agents looked highly effective in type 2 diabetes across a pair of new studies.
Recap by typeshit. Post by TCTMD on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Pooled ATTAIN-1 and ATTAIN-2 results showed about 14% average weight loss and up to 12.5 cm off the waist across menopausal stages.
Dr Sara Kayat flags the UK seizure, which included counterfeit pens labelled as retatrutide and tirzepatide, and explains why it matters for buyers.
Loading…